Get started
Author

Susan Tantawi

Institution: Galecto (Denmark)
Observed institution: Galecto (Denmark)
ORCID: 0009-0000-7671-0568
Observed ORCID: 0009-0000-7671-0568
OpenAlex ID: A5077930008
Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis
2020 · Nikhil Hirani, Alison C. MacKinnon, et al. · European Respiratory Journal · 243
PDF
An Orally Active Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 Blockade
2019 · Lynda Vuong, Eleni Kouverianou, et al. · Cancer Research · 148
Discovery and Optimization of the First Highly Effective and Orally Available Galectin-3 Inhibitors for Treatment of Fibrotic Disease
2022 · Fredrik R. Zetterberg, Alison MacKinnon, et al. · Journal of Medicinal Chemistry · 113
Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participants
2023 · Vassilios Aslanis, Robert J. Slack, et al. · Cancer Chemotherapy and Pharmacology · 53
PDF
Relative bioavailability and food effect of the galectin-3 inhibitor selvigaltin (GB1211) administered as a tablet in healthy participants (GALBA-1)
2024 · Vassilios Aslanis, Khalid Abd-Elaziz, et al. · Cancer Chemotherapy and Pharmacology · 3
Data from An Orally Active Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 Blockade
2023 · Lynda Vuong, Eleni Kouverianou, et al.
Supplementary Material from An Orally Active Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 Blockade
2023 · Lynda Vuong, Eleni Kouverianou, et al.
Supplementary Figures 1 and 2 from An Orally Active Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 Blockade
2023 · Lynda Vuong, Eleni Kouverianou, et al.
Supplementary Figures 3 and 4 from An Orally Active Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 Blockade
2023 · Lynda Vuong, Eleni Kouverianou, et al.
PDF
Supplementary figures 7 and 8 from An Orally Active Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 Blockade
2023 · Lynda Vuong, Eleni Kouverianou, et al.
PDF
Supplementary Figures 5 and 6 from An Orally Active Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 Blockade
2023 · Lynda Vuong, Eleni Kouverianou, et al.
Supplementary Figures 5 and 6 from An Orally Active Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 Blockade
2023 · Lynda Vuong, Eleni Kouverianou, et al.
PDF
Supplementary figures 7 and 8 from An Orally Active Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 Blockade
2023 · Lynda Vuong, Eleni Kouverianou, et al.
Correction to: "Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis." Nikhil Hirani, Alison C. MacKinnon, Lisa Nicol, et al. Eur Respir J 2021; 57: 2002559
2022 · Nikhil Hirani, Alison C. MacKinnon, et al. · Newcastle University ePrints (Newcastle Univesity)
Works count: 14
Citation count: 560
H-index: 4
I10-index: 4
Year
Topic
Type